Wyeth's R&D chief tightlipped on Pfizer (Corporate Dealmaker)Wyeth’s (NYSE:WYE) head of pharmaceutical research Mikael Dolsten has already accepted a job at Pfizer Inc. (NYSE:PFE), which is buying his company for $68 billion, but at an industry conference in San Francisco on Wednesday he barely .
Ipsen, Pharnext enter research, development & marketing agreement (PharmaBiz)
Helix BioPharma Corp. (TSX, FSE: HBP) announced that Dr. Heman Chao, chief scientific officer at Helix BioPharma Corp., will be presenting a scientific poster describing L-DOS47 analytical method development findings at the 2009 American Association of Pharmaceutical Scientists (”AAPS”) National Biotechnology Conference, which runs from June 21st to 24th at the Washington State Convention and Trade Center in Seattle, Washington. pharmaceutical research and development
Cephalon, Inc. (Nasdaq: CEPH) announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. pharmaceutical research and development
